TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics has received a $4.5 million R&D tax incentive from the Australian Government, recognizing its research and development activities in 2025. This financial boost supports Chimeric’s ongoing efforts in advancing its cell therapy programs, potentially enhancing its position in the oncology treatment market and benefiting stakeholders through continued innovation in cancer therapies.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical stage cell therapy company based in Australia, specializing in innovative cancer treatments. The company focuses on developing autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across various oncology areas. Chimeric is engaged in multiple clinical stage programs, including CHM CDH17, CHM CORE-NK, and CHM CLTX, each targeting different cancer types.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.11M
See more data about CHM stock on TipRanks’ Stock Analysis page.